Philadelphia, PA — March 3, 2026 — Leads & Copy — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) presented a scientific poster on its diagnostic approach to identify antibody drug receptors in sputum at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2026 annual meeting in Philadelphia on March 1.
The research focuses on identifying receptors for dupilumab, a therapy for asthma and chronic obstructive pulmonary disease (COPD), and benralizumab, another asthma therapy. The company’s pipeline tests aim to guide personalized treatment decisions and improve disease monitoring for asthma and COPD sufferers.
William Bauta, PhD, Chief Science Officer of bioAffinity Technologies, presented the poster, titled “Sputum as a Diagnostic Tool for the Treatment of Asthma.” The research details the Company’s development of clinical diagnostics that may help physicians match asthma and COPD patients with effective therapies and monitor inflammatory changes to improve outcomes and lower healthcare costs.
According to Dr. Bauta, approximately 650 million children and adults globally are impacted by Asthma and COPD. He added that while there are effective treatments, many patients must try multiple treatments before finding an effective therapy.
bioAffinity’s technology platform is used with its commercial test, CyPath® Lung, a noninvasive diagnostic test for lung cancer with demonstrated high sensitivity and specificity for patients with small pulmonary nodules in detecting lung cancer as early as curative Stage 1A.
CyPath® Lung utilizes advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. The test incorporates a fluorescent porphyrin that is taken up by cancer and cancer-related cells. Clinical study results demonstrated 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in high-risk patients with small indeterminate lung nodules less than 20 millimeters.
bioAffinity Technologies, Inc. focuses on noninvasive diagnosis of early-stage cancer and other diseases of the lung, and broad-spectrum cancer treatments. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies.
Source: bioAffinity Technologies, Inc.
